En vivo
Clinical OMICsPioneering Innovation in Transplant DiagnosticsFierceBiotechRoche nabs EU approval on label expansions for companion dx platformFierceBiotechGenentech executes another round of layoffs, with 3 VPs axedScienceLaser-boosted microscopes could reveal new drug targets, sharpen views inside cellsScienceThe ocean current that warms Europe may be more resilient than fearedClinical OMICsCyclana Bio Is Exploring the Extracellular Matrix to Treat EndometriosisFierceBiotechAI use is surging across HHS, jumping 148% at the FDA in 2025, Bipartisan Policy Center data findsClinical OMICsHigher Vitamin C Levels in Blood Linked to Healthier Aging BrainsClinical OMICsStopping Neurodegeneration in Place with VaccinesClinical OMICsRemote Monitoring Benefits Unclear After Hospitalization for Serious InfectionFierceBiotechNovo reports data breach, tells clinical trial patients to 'remain vigilant'Endpoints NewsThe seeming inevitability of rising healthcare costs
BioWorld 22 ene 2026

Janux’s tumor-activated platform draws BMS in potential $850M deal

Janux’s tumor-activated platform draws BMS in potential $850M deal

Original
Contenido no disponible. Consulta la fuente original.